Cargando…
The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients
BACKGROUND: In Saudi Arabia, a diet for life policy has been adopted in the management of amino acid metabolism disorders for years. However, the specially designed low protein products/medical foods - which are one of the important treatment tools - were not available up until several years ago in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
King Faisal Specialist Hospital and Research Centre
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363253/ https://www.ncbi.nlm.nih.gov/pubmed/30805535 http://dx.doi.org/10.1016/j.ijpam.2018.04.001 |
_version_ | 1783393079959486464 |
---|---|
author | Handoom, Bedour Megdad, Eman Al-Qasabi, Dana Al Mesned, Munirah Hawary, Reem Al-Nufiee, Samir Al-Hassnan, Zuhair Alsayed, Moeenaldeen Dia Eldali, Abdelmoneim |
author_facet | Handoom, Bedour Megdad, Eman Al-Qasabi, Dana Al Mesned, Munirah Hawary, Reem Al-Nufiee, Samir Al-Hassnan, Zuhair Alsayed, Moeenaldeen Dia Eldali, Abdelmoneim |
author_sort | Handoom, Bedour |
collection | PubMed |
description | BACKGROUND: In Saudi Arabia, a diet for life policy has been adopted in the management of amino acid metabolism disorders for years. However, the specially designed low protein products/medical foods - which are one of the important treatment tools - were not available up until several years ago in Saudi Arabia (SA). Our aim was to measure the compliance and quality of life in patients affected with these disorders followed in the metabolic nutrition clinic at King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh, SA. METHODOLOGY: We used a non-randomized retrospective/prospective study which utilized the growth parameters, biochemical data of patients plus questionnaires collected from patients and their family/caregivers. A total of n = 182 patients affected with selected amino acid metabolism disorders were enrolled. Some were excluded n = 84 for various reasons. Sample analyzed were: Phenylketonuria (PKU) (44), Maple Syrup Urine Disease (MSUD) (30), Tyrosinemia (TYR) (17) and Homocystinuria (HCU) (7). Tandem Mass Spectrometry (TMS) used to quantitate plasma amino acid concentrations. Data was obtained using (COMPLE) Microsoft-Access which was designed by the metabolic nutrition clinic at KFSH&RC-Riyadh. Student's paired t-test was used to investigate relationship between variables. RESULTS: The main findings were the improvement of selected amino acid levels pre and post the usage of medical foods. In PKU patients, the TMS Phenylalanine (PHE) levels post usage was significantly decreased (P value < .0001). This was also the case in MSUD patients with significant decrease in Leucine & Isoleucine levels (P value .0008) but not in Valine levels (P value .1148) as 36.7% of them received Valine supplements while enrolled in the study. CONCLUSION: Low protein products availability was successful in improving outcomes for selected amino acid metabolic disorders. However, due to compliance issues and impracticality of the diet, the results were not significant in all enrolled patients. |
format | Online Article Text |
id | pubmed-6363253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | King Faisal Specialist Hospital and Research Centre |
record_format | MEDLINE/PubMed |
spelling | pubmed-63632532019-02-25 The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients Handoom, Bedour Megdad, Eman Al-Qasabi, Dana Al Mesned, Munirah Hawary, Reem Al-Nufiee, Samir Al-Hassnan, Zuhair Alsayed, Moeenaldeen Dia Eldali, Abdelmoneim Int J Pediatr Adolesc Med Original Research Article BACKGROUND: In Saudi Arabia, a diet for life policy has been adopted in the management of amino acid metabolism disorders for years. However, the specially designed low protein products/medical foods - which are one of the important treatment tools - were not available up until several years ago in Saudi Arabia (SA). Our aim was to measure the compliance and quality of life in patients affected with these disorders followed in the metabolic nutrition clinic at King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh, SA. METHODOLOGY: We used a non-randomized retrospective/prospective study which utilized the growth parameters, biochemical data of patients plus questionnaires collected from patients and their family/caregivers. A total of n = 182 patients affected with selected amino acid metabolism disorders were enrolled. Some were excluded n = 84 for various reasons. Sample analyzed were: Phenylketonuria (PKU) (44), Maple Syrup Urine Disease (MSUD) (30), Tyrosinemia (TYR) (17) and Homocystinuria (HCU) (7). Tandem Mass Spectrometry (TMS) used to quantitate plasma amino acid concentrations. Data was obtained using (COMPLE) Microsoft-Access which was designed by the metabolic nutrition clinic at KFSH&RC-Riyadh. Student's paired t-test was used to investigate relationship between variables. RESULTS: The main findings were the improvement of selected amino acid levels pre and post the usage of medical foods. In PKU patients, the TMS Phenylalanine (PHE) levels post usage was significantly decreased (P value < .0001). This was also the case in MSUD patients with significant decrease in Leucine & Isoleucine levels (P value .0008) but not in Valine levels (P value .1148) as 36.7% of them received Valine supplements while enrolled in the study. CONCLUSION: Low protein products availability was successful in improving outcomes for selected amino acid metabolic disorders. However, due to compliance issues and impracticality of the diet, the results were not significant in all enrolled patients. King Faisal Specialist Hospital and Research Centre 2018-06 2018-06-14 /pmc/articles/PMC6363253/ /pubmed/30805535 http://dx.doi.org/10.1016/j.ijpam.2018.04.001 Text en © 2018 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Article Handoom, Bedour Megdad, Eman Al-Qasabi, Dana Al Mesned, Munirah Hawary, Reem Al-Nufiee, Samir Al-Hassnan, Zuhair Alsayed, Moeenaldeen Dia Eldali, Abdelmoneim The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients |
title | The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients |
title_full | The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients |
title_fullStr | The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients |
title_full_unstemmed | The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients |
title_short | The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients |
title_sort | effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363253/ https://www.ncbi.nlm.nih.gov/pubmed/30805535 http://dx.doi.org/10.1016/j.ijpam.2018.04.001 |
work_keys_str_mv | AT handoombedour theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT megdademan theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT alqasabidana theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT almesnedmunirah theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT hawaryreem theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT alnufieesamir theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT alhassnanzuhair theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT alsayedmoeenaldeendia theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT eldaliabdelmoneim theeffectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT handoombedour effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT megdademan effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT alqasabidana effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT almesnedmunirah effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT hawaryreem effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT alnufieesamir effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT alhassnanzuhair effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT alsayedmoeenaldeendia effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients AT eldaliabdelmoneim effectsoflowproteinproductsavailabilityongrowthparametersandmetaboliccontrolinselectedaminoacidmetabolismdisorderspatients |